Mortality in Patients with the Acquired Immunodeficiency Syndrome Treated with either Foscarnet or Ganciclovir for Cytomegalovirus Retinitis

Open Access
Publisher Website
Google Scholar
Abstract
We performed a multicenter, randomized, unblinded clinical trial (the Foscarnet—Ganciclovir Cytomegalovirus Retinitis Trial) designed to compare ganciclovir with foscarnet in the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome (AIDS). Of 234 patients, 127 were randomly assigned to ganciclovir and 107 to foscarnet; the study drugs were administered according to a common protocol at the 11 participating clinical centers. Antiretroviral therapy (with zidovudine, didanosine, or dideoxycytidine) was given as dictated by best medical judgment. The patients were followed for the progression of retinitis, visual loss, and death.